Institution scientifique

Seqirus (United States)

Cambridge · US · company

321Publications signalées

7858Citations signalées

12Thèmes principaux

Principaux domaines

Influenza Virus Research StudiesRespiratory viral infections researchVaccine Coverage and HesitancySARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinationsPneumonia and Respiratory InfectionsCOVID-19 epidemiological studiesImmunotherapy and Immune ResponsesAnimal Disease Management and EpidemiologyImmune Response and InflammationViral Infections and Outbreaks ResearchViral gastroenteritis research and epidemiology

Évolution annuelle

19921

20031

20061

20101

20131

20165

201710

201814

201915

202028

202141

202227

202345

202449

202537

202635

Publications récentes

Accès ouvert 2026 articleOpenAlex

Clinical and public health economic impact of rapid strain-matched vaccination in influenza pandemic mitigation: A UK-like population dynamic transmission model

Sam Lovick, Malur Sudhanva, Alexander T. Kennedy, Ray Longstaff et autres

0 citationsHuman Vaccines & Immunotherapeutics

Accès ouvert 2026 articleOpenAlex

Heterologous prime-boost vaccination against H5 avian influenza: Safety and immunogenicity of a MF59-adjuvanted, cell-culture derived H5N6 vaccine

Esther van Twuijver, Eve Versage, Robert L. Jacobs, Matthew Hohenboken

0 citationsHuman Vaccines & Immunotherapeutics

Accès ouvert 2026 articleOpenAlex

Adjuvanted and high-dose influenza vaccines had comparable effectiveness against test-confirmed influenza outcomes including hospitalizations in overall and high-risk older adults in the 2022–2023 and 2023–2024 seasons

Mahrukh Imran, Benjamin Chastek, Tim Bancroft, Noah Webb et autres

0 citationsInternational Journal of Infectious Diseases

Accès ouvert 2026 articleOpenAlex

Emerging Prescribing Patterns of Vazkepa (icosapent ethyl) by Gender and Age in Australia

M. Dooley, C. Morgan

0 citationsHeart Lung and Circulation

Accès ouvert 2026 preprintOpenAlex

Epistasis facilitates the long-term antigenic evolution of the influenza B virus hemagglutinin

Lara S. U. Schwab, Ruopeng Xie, Ellie Reilly, Malet Aban et autres

0 citationsbioRxiv (Cold Spring Harbor Laboratory)

Accès ouvert 2026 articleOpenAlex

Evaluating the cost-effectiveness of adjuvanted influenza vaccine in the older adult population in the Netherlands

Samuel Braak, Joaquin F. Mould-Quevedo, Jan Wilschut, Gerrit A. van Essen et autres

0 citationsHuman Vaccines & Immunotherapeutics

2026 conference-abstractOpenAlex

P14 COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF THE TRIVALENT ADJUVANTED INFLUENZA VACCINE IN PEOPLE OVER 50 YEARS OF AGE FOR ARGENTINA

Leandro J. Pastori, Constanza Silvestrini Viola, Tomás Alconada, Gonzalo Pereira et autres

0 citationsValue in Health

2026 articleOpenAlex

Modern Approaches to the Disclosure of ESG Information in the Corporate Reporting of FMCG-Companies

Svyetlana Grishkina, K. Toletova

0 citationsAuditor

Accès ouvert 2026 articleOpenAlex

Using an RNA binding protein to detect mRNA on lipid nanoparticles

Meagan McMahon, Hareth Al-Wassiti, Kirsten Vandenberg, Karen Laurie et autres

0 citationsScientific Reports

Accès ouvert 2026 articleOpenAlex

ModiCal: A Targeted Calibration Workflow for Site-Specific m 5 C Validation by Nanopore Direct RNA Sequencing

Zeynep Özrendeci, Stefan Mündnich, Stefan Pastore, Chia Ching Wu et autres

0 citationsACS Chemical Biology

Accès ouvert 2026 articleOpenAlex

Vaccines as Global Health Security Infrastructure: Insights from a Descriptive Analysis of Vaccines Europe Members’ Clinical Pipelines

Charlotte Vernhes, Kateryna Khmilevska, Alexis Caron, Emanuele Ciglia et autres

0 citationsVaccines

Accès ouvert 2026 articleOpenAlex

Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults

Amber Hsiao, Thomas Leong, Bruce Fireman, John Hansen et autres

3 citationsJAMA Network Open

Identifiant ROR

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.